Data demonstrating pre-clinical efficacy and safety of Affibody’s radio-therapeutic anti-HER2 agent ABY-271 presented at EANM annual congress

News

October 20, 2024

Affibody AB (“Affibody”) announces presentation of data from IND enabling preclinical studies with the radiotherapeutic agent 177Lu-ABY-271 for treatment of HER2 expressing metastatic disease. The data will be presented today at the Annual Congress of the European Association of Nuclear Medicine.

The data will be presented in the radiopharmaceuticals sciences and translational therapy session by investigator Yongsheng Liu in the Professor Tolmachev group, Uppsala University. Strong therapeutic effect of HER2 targeted 177Lu is demonstrated with significantly longer survival for the treatment group as compared to trastuzumab standard of care treatment.

“These data suggest that our drug candidate could reach meaningful levels of drug in tumors of patients with metastatic disease” says Fredrik Frejd, CSO, Affibody AB. “The drug is in late IND enabling development, and we anticipate early clinical data by mid next year”, he continues.

The presentation details are as follows:
Title: A Novel 177Lu-labelled Affibody Molecule with Deimmunized ABD: Enhanced Biodistribution Profile and Anti-tumour Efficacy
Presentation Number: OP-085
Session Number: 304
Session Title: M2M Track – TROP
Session: Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee: Antibodies & Co.
Session Timing & Location: October 20, 2024; 09:45 – 11:15a.m. CET, Hall X1–X4
Presentation Timing: October 20, 2024; 10.15-10.25 a.m. CET

Additional information about EANM 2024 is available at: https://eanm24.eanm.org/.

About ABY-271

ABY-271 is a radiotherapeutic candidate aimed at tumor cells that express HER2, regardless of their position in the body. The project builds on previous clinical research insights from the development of tezatabep (ABY-025), showing that the candidate substance can bind to HER2 independently of the tumor origin. ABY-271 emits therapeutic beta radiation, exerting irreversible damage to the cancer cells upon binding. The drug candidate is currently in late IND enabling development.

About Affibody® molecules

Affibody® molecules are a novel drug class of small therapeutic proteins with characteristics surpassing monoclonal antibodies (mAbs) and antibody fragments. The Company has created a large library consisting of more than ten billion Affibody® molecules, all with unique binding sites, from which binders to given targets are selected. Affibody® molecules are only 6 kDa in size.

They have demonstrated clinical utilities both as tumor-targeting moieties through their small size and as efficacious disease blocking agents in autoimmune indications by utilizing the inherent properties that allow multi-specific formats.

About Affibody

Affibody is a clinical stage integrated biopharmaceutical company with a broad product pipeline focused on developing innovative bi- and multi-specific next generation biopharmaceutical drugs based on its unique proprietary technology platform, Affibody® molecules.

Through its validated business model, the company has a proven capability of identifying and prioritizing strategic projects in a timely and de-risked way. Affibody has established several partnerships for the development and commercialization of its innovations with international pharmaceutical companies.

Affibody’s main shareholder Patricia Industries is a part of Investor AB.

Further information can be found at: www.affibody.com.

Data demonstrating pre-clinical efficacy and safety of Affibody’s radio-therapeutic anti-HER2 agent ABY-271 presented at EANM annual congress